Eevia Health has published a whitepaper summing a study that compares the bioequivalence between Fenoprolic® and Pycnogenol®, two leading pine bark extracts known for their high levels of oligomeric proanthocyanidins (OPCs). Fenoprolic® is derived from the bark of Arctic pine trees (Pinus sylvestris) sourced from the pristine forests of Finnish Lapland. This region’s pure environment ensures the highest quality raw materials, resulting in a potent extract standardized to 70 ± 5% OPCs.  Pycnogenol® is made from French pine, Pinus Pinnastre (or Maritima) and is also specified to 70 ± 5% OPCs.

The comprehensive study, conducted using Eurofin’s BioMAP® Diversity PLUS® Panel, reveals that Fenoprolic® offers nearly identical bioactivity to Pycnogenol® across 148 biomarkers. Hence, the study demonstrates that Fenoprolic® likely delivers equivalent therapeutic benefits to Pycnogenol®, making it a cost-effective choice for various health applications in the nutraceutical market.

Figure: BioMAP Profile Plot Comparison of Fenoprolic® and Pycnogenol

Download the Whitepaper

To learn more about the groundbreaking research and the benefits of Fenoprolic®, download the full whitepaper here.